![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/07\/20260722_RevolutionMedicines_Image-768x432.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Revolution Medicines<\/p>\n Event Type<\/strong><\/p>\n Regulatory Filing Acceptance (FDA NDA)<\/p>\n Modality<\/strong><\/p>\n Small-Molecule RAS(ON) Inhibitor (Multi-Selective)<\/p>\n Asset<\/strong><\/p>\n Daraxonrasib<\/p>\n Target<\/strong><\/p>\n RAS (Multi-Variant, GTP-Bound)<\/p>\n Disease Area<\/strong><\/p>\n Metastatic Pancreatic Ductal Adenocarcinoma<\/p>\n The FDA accepted Revolution Medicines’ NDA for oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The filing is supported by RASolute 302, where median overall survival was 13.2 months versus 6.7 months with chemotherapy, corresponding to a hazard ratio of 0.40. Acceptance moves a potentially class-defining pan-RAS medicine into review under the Commissioner’s National Priority Voucher pilot, while manufacturing, detailed safety, and durability remain central review questions.<\/p>\n The application covers previously treated metastatic PDAC with or without an identified tumor RAS mutation. Daraxonrasib previously received Breakthrough Therapy and Orphan Drug designations and was selected for the FDA Commissioner’s National Priority Voucher pilot program.<\/p>\n The global randomized Phase 3 RASolute 302 trial compared daraxonrasib 300 mg orally once daily with investigator’s-choice cytotoxic chemotherapy. It met all primary and key secondary endpoints, including progression-free and overall survival, and showed delayed deterioration in cancer-related pain, global health status, and quality of life.<\/p>\n The intent-to-treat analysis reported median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, with a hazard ratio of 0.40 and a p-value below 0.0001. The European Medicines Agency has also begun a phased review under its Cancer Medicines Pathfinder project.<\/p>\n Metastatic PDAC has long been dominated by cytotoxic combinations, with limited options after progression. A randomized survival advantage of this magnitude, accompanied by patient-reported benefit, is more persuasive than a response-rate signal and could establish a new targeted standard in the second-line setting.<\/p>\n The broad enrollment strategy matters. More than 90% of pancreatic cancers are RAS-driven, but routine assays may miss variants or provide incomplete tissue. Activity in the intent-to-treat population could support a simpler treatment pathway than mutation-specific inhibitors, although subgroup consistency remains important.<\/p>\n Daraxonrasib is a noncovalent tri-complex inhibitor that targets active, GTP-bound RAS and interferes with its interaction with downstream effectors. Its multi-selective design covers several common mutant forms and wild-type RAS signaling rather than one codon-specific variant.<\/p>\n Broad RAS suppression creates both the opportunity and the risk. It can address heterogeneous tumors and adaptive signaling, but normal-tissue RAS biology may narrow the therapeutic window. Detailed dose intensity, adverse-event management, and resistance mechanisms will determine how durable the class can be.<\/p>\n NDA acceptance confirms that the application is sufficiently complete for substantive review; it does not establish approvability. The priority-voucher pathway may compress the review timeline, placing pressure on manufacturing readiness, labeling negotiations, and postmarketing commitments.<\/p>\n Revolution Medicines is running additional Phase 3 studies in pancreatic and lung cancer. Approval in PDAC would validate the company’s RAS(ON) platform and strengthen the rationale for mutant-selective follow-ons such as zoldonrasib, elironrasib, and RMC-5127.<\/p>\n The success expands RAS drug development beyond KRAS G12C. Competing G12D, G12V, pan-KRAS, and pathway-combination programs will be judged against randomized survival evidence rather than early response rates.<\/p>\n If approved, practical adoption should be rapid because the comparator is intravenous chemotherapy and the disease has severe unmet need. Drug interactions, tolerability, access, and sequencing after first-line regimens will still shape real-world use.<\/p>\n Pancreatic ductal adenocarcinoma is an aggressive cancer commonly diagnosed after it has spread. Most tumors are driven by activating RAS alterations, which sustain MAPK signaling, proliferation, metabolic adaptation, and resistance. Five-year survival for metastatic disease remains extremely low.<\/p>\n Revolution Medicines develops RAS(ON) inhibitors. Daraxonrasib is an oral multi-selective agent that forms a noncovalent complex with active RAS and an intracellular chaperone, preventing RAS from engaging downstream effectors. The company also develops mutation-selective RAS(ON) medicines for G12C, G12D, G12V, and other variants.<\/p>\n This is a high-importance regulatory and modality signal. The underlying randomized survival result is strong enough to reset expectations for RAS-directed therapy in pancreatic cancer and moves the field beyond narrow mutation-specific proof of concept.<\/p>\n The remaining analysis should focus on the full safety dataset, subgroup consistency, quality-of-life durability, resistance at progression, and whether broad RAS inhibition can be moved earlier or combined safely. NDA acceptance is an important process milestone; the transformative evidence remains the Phase 3 survival effect.<\/p>\n Signal strength:<\/strong> 5\/5 \u2014 High. Importance:<\/strong> High \u2014 the filing is supported by a large randomized survival improvement in one of oncology’s most treatment-resistant diseases and could validate a new RAS drug class. Confidence:<\/strong> High for the acceptance, trial design, and reported survival results; medium regarding label breadth, review timing, and commercial durability pending FDA assessment and full data.<\/p>\n","protected":false},"excerpt":{"rendered":" The FDA accepted Revolution Medicines’ NDA for oral daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma. The filing is supported by RASolute 302, where median overall survival was 13.2 months versus 6.7 months with…<\/p>\n","protected":false},"author":1,"featured_media":2104,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[167,166],"class_list":["post-2092","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-pancreatic-cancer","tag-revolution-medicines"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2092","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=2092"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2092\/revisions"}],"predecessor-version":[{"id":2105,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/2092\/revisions\/2105"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/2104"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=2092"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=2092"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=2092"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Clinical Significance<\/h4>\n
Mechanism and Class Validation<\/h4>\n
Regulatory and Development Implications<\/h4>\n
Competitive Landscape<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n